Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
October 11, 2021 07:00 ET
|
Flexion Therapeutics, Inc.
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock...
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
September 03, 2021 09:00 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
September 02, 2021 07:30 ET
|
Flexion Therapeutics, Inc.
AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 ...
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
August 25, 2021 07:30 ET
|
Flexion Therapeutics, Inc.
Initial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patientsData from the trial, including the expansion cohort,...
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)
August 09, 2021 16:30 ET
|
Flexion Therapeutics, Inc.
Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data...
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
August 04, 2021 16:01 ET
|
Flexion Therapeutics, Inc.
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by...
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
July 29, 2021 16:15 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the...
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
July 12, 2021 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to...